학술논문
Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial
Document Type
Article
Author
Becker, Jürgen C; Ugurel, Selma; Leiter, Ulrike; Meier, Friedegund; Gutzmer, Ralf; Haferkamp, Sebastian; Zimmer, Lisa; Livingstone, Elisabeth; Eigentler, Thomas K; Hauschild, Axel; Kiecker, Felix; Hassel, Jessica C; Mohr, Peter; Fluck, Michael; Thomas, Ioannis; Garzarolli, Marlene; Grimmelmann, Imke; Drexler, Konstantin; Spillner, Alexandra N; Eckhardt, Sebastian; Schadendorf, Dirk; van Akkoi, Alexander; van Houdt, Winan; Wilhelm, Tabea; Farmer, Kimberly; Ulrich, Claas; Gambichler, Thilo; Bluhm, Leonie; Schinagl, Heidemarie; Kellner, Ivonne; Herbst, Rudolf; Meiß, Frank; Rafei-Shamsabadi, David; Sell, Sabine; Kaatz, Martin; Wulfken, Lena; Hartmann, Martin; Kähler, Katharina; Ziemer, Mirjana; Simon, Jan; Terheyden, Patrick; Thaci, Diamant; Loquai, Carmen; Mitzel-Rink, Heidrun; Grabbe, Stephan; Stege, Henner; Gaiser, Maria; Utikal, Jochen; Berking, Carola; Heinzerling, Lucie; Schlaak, Max; Tomsitz, Dirk; Dyballa, Jörg; Magnolo, Nina; Weishaupt, Carsten; Berneburg, Mark; Garbe, Claus; Flatz, Lukas; Gesierich, Anja; Schilling, Bastian
Source
The Lancet; September 2023, Vol. 402 Issue: 10404 p798-808, 11p
Subject
Language
ISSN
01406736; 1474547X
Abstract
Merkel cell carcinoma (MCC) is an immunogenic but aggressive skin cancer. Even after complete resection and radiation, relapse rates are high. PD-1 and PD-L1 checkpoint inhibitors showed clinical benefit in advanced MCC. We aimed to assess efficacy and safety of adjuvant immune checkpoint inhibition in completely resected MCC (ie, a setting without an established systemic standard-of-care treatment).